Published in Gene Therapy Weekly, August 19th, 2004
DCs "genetically engineered to express high levels of Fas ligand (FasL/CD95L) have been demonstrated to delete T cells in an antigen specific manner in several different animal models in vivo," immunologists in Germany explained. "However, the immunomodulatory capacity of primary human FasL-expressing Killer-DC has not been determined."
In a study conducted by S. Hoves and colleagues at the University of Regensburg, "human Killer-DC were generated from mature monocyte-derived DC using the inducible CRE/LoxP adenoviral vector system, and the immunoregulatory...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.